On February 1, 2023 HanAll Biopharma Co., Ltd. (KRX: 009420. KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for 2022 and provided business updates (Press release, HanAll Biopharma, FEB 1, 2023, View Source [SID1234626743]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Total revenues for 2022 were 110 billion won, an 8% increase year-on-year, mainly driven by continued strong sales from the key products and milestone revenues from the licensed partners, including $10 million milestone payment from Immunovant for the initiation of the MG Phase 3 trial. Net income for the year was 2 billion won, offset by increased R&D expenses.
"HanAll continued to transform into innovative global biopharma in 2022 by strengthening clinical development capability and expanding open collaboration network while continuing to deliver solid sales performance. We were able to launch a share buyback program to return value to our stakeholders," said Sean Jeong, M.D., CEO of HanAll Biopharma.
"Moving into the 50th years since our foundation, 2023 will be a pivotal year for HanAll with top-line data readout of tanfanercept and progress in anti-FcRn programs. We will continue to make our best efforts to contribute to the patients," he added.
Full-Year 2022 BUSINESS UPDATE
Pipeline Development Highlights
A comprehensive update on HanAll’s pipeline development below includes an overview of HanAll’s research along with the list of compounds, targeted indications, and developmental phase.
Autoimmune Diseases Programs
Batoclimab (Code name: HL161BKN)
A novel, fully human, subcutaneously administered antibody targeting FcRn, with the potential to address multiple IgG-mediated autoimmune diseases. Batoclimab is designed to selectively bind to and inhibit FcRn, which plays a role in recycling IgG, thus leading to a reduction in IgG antibodies.
In the second half of 2022, HanAll Biopharma received approval from the Pharmaceuticals and Medical Devices Agency to initiate a Phase 3 study of batoclimab in myasthenia gravis (MG) in Japan, and plan to initiate the study in the first half of 2023. HanAll is exploring the options of developing batoclimab in thyroid eye disease (TED) in Japan.
HanAll’s licensed partner, Immunovant is conducting global Phase 3 trials with batoclimab in myasthenia gravis (MG) and thyroid eye disease (TED). The top-line results for the pivotal Phase 2b trial in chronic inflammatory demyelinating polyneuropathy (CIDP) is expected in the first half of 2024. In Graves’ disease (GD), a Phase 2 trial is planned to be initiated in early 2023. Immunovant will finalize the trial design in warm autoimmune hemolytic anemia (WAIHA) in early 2023, based on recent FDA interaction.
Harbour BioMed, another licensed partner of HanAll who is developing batoclimab in China, signed a sub-licensing deal with CSPC NBP Pharmaceutical Co., Ltd. in October 2022. Under the agreement, CSPC was granted the rights to develop and commercialize batoclimab in Greater China. The company is developing batoclimab in an array of autoimmune disorders including myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), and immune thrombocytopenia (ITP). The top-line data for the ongoing Phase 3 study in MG are expected in the first half of 2023.
HL161ANS (Immunovant code name: IMVT-1402)
A second novel, fully human, subcutaneous antibody molecule that inhibits FcRn-mediated recycling of IgG, designed to deliver maximum lgG reductions while minimizing interference with albumin binding.
In September 2022, Immunovant unveiled a new FcRn inhibitor HL161ANS (Immunovant code name: IMVT-1402), originally discovered and developed by HanAll. Immunovant plans to start a Phase 1 trial for HL161ANS in early 2023 with the initial data read out expected in in mid-2023.
Eye Disease Programs
Tanfanercept (Code name: HL036)
A novel, topical biologic therapy for eye diseases including dry eye disease (DED) by inhibiting TNF alpha, which is a key mediator of ocular inflammation.
HanAll Biopharma and Daewoong Pharmaceutical are progressing with the second Phase 3 VELOS-3 study in patients with moderate to severe DED to examine the safety and efficacy of tanfanercept, at nine clinical sites in the US. The study enrollment is complete and the top-line results from the VELOS-3 study are expected in the first half of 2023.
Harbour BioMed, HanAll’s licensed partner in China, announced in October 2022, that they decided to close its Phase 3 study in DED without enrolling additional patients to the study, following the recommendation from the Independent Data Monitoring Committee (IDMC) upon review of the insufficient efficacy trend observed during the second interim analysis. The study in China is different from the ongoing US study (VELOS-3) in key inclusion criteria, primary endpoints, and patient demographics reflecting different medical practices and regulatory requirements. HanAll is in discussion with Harbour BioMed regarding the next steps for the development of tanfanercept in China.
Oncology Programs
HL187/ HL186
Monoclonal antibodies that respectively target TIM-3 and TIGIT, for the potential treatment of cancer, being developed in collaboration with Daewoong Pharmaceutical Co.
HanAll is continuing with the pre-clinical development of HL187 and is preparing for IND submission in 2023. HL186 is currently in the discovery phase.
FINANCIAL HIGHLIGHTS (CONSOLIDATED)
Key Highlights
(KRW in billion)
2022
2021
% change
Sales
110
102
+8 %
Gross Profit
62
60
+3 %
Selling, marketing and administrative expenses
44
40
+11 %
Research and development expenses
16
10
+58 %
Operating income
2
10
-85 %
Net Income
2
9
-78 %
Sales recorded 110 billion won in 2022, an 8.3% increase compared to 2021. The sales in the pharmaceutical division remained strong with its major products including Normix, Eligard, and Biotop.
R&D expenses showed a 58% increase compared to 2021, with a record of 16 billion won.
Net income was 2 billion won, a 78% decrease, compared to the same period in the year of 2021, mainly due to increased investments in R&D.